AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05437549 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: MRI prior to PVI, acutely after PVI, and 3 months after PVI
Study NCT06038019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral food challenge
Description: Patients will undergo oral food challenge with increasing amounts of food allergen
Study NCT05548686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted physical activity
Description: 3 sessions of adapted physical activity per week during 12 weeks for each patient
Study NCT06642974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education module on learning disabilities
Description: Data will be collected for a period of one -year. samples will be equally distributed among experimental and control group. Socio -demographic data and knowledge and attitude of primary school teachers on learning disability will be assessed by interview method using questionnaire. Control group will receive general information on children with learning disabilities while experimental group will receive education training program. After 15 days again education program will be repeated as a reinforcement. Pre and posttest will be conducted for both the groups at one-month interval. Required data will be collected for one-year period by interview method using questionnaire. Competency assessment will be done by using checklist on identification of learning disabilities Teachers' competency for experimental group then the competency will be verified by education counselor . As a follow up of the research study, after one-month interval no of referral by each teacher will be collected to m
Study NCT06642974 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pamphlet on learning disability
Description: Education pamphlets will be provided to total of 67 samples
Study NCT05620342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iC9.GD2.CAR.IL-15 T Infusion
Description: iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection over 5 - 10 minutes.
Study NCT06500663 — intervention group
Intervention type: OTHER
Intervention: haemodialysis
Description: haemodialysis effect on thyroid function
Study NCT04000477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytobrush
Description: the brush would be inserted in full until the display of the brush in the endocervical canal disappears. A neck quadrant scan (= quarter turn) will be performed from front to back while simultaneously rotating the brush clockwise, for a total of 3 laps. This would represent 4 sweeps per turn, ie 12 sweeps in total
Study NCT04000477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kevorkian curette
Description: the colposcopist holds the curette horizontally and scrapes the endocervical canal all the way around. He realizes 1 small firm and linear movement by quarter turn or 4 movements to realize a complete turn. During this act, the curette must remain inside the canal, and during its extraction, care should be taken not to rotate it so as not to spill the collected tissue contained in the basket of the curette. The tissue material thus obtained must be rapidly immersed in formalin
Study NCT05046756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth App and wearable device
Description: An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for colon cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
Study NCT06546033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of different types of diet
Description: application of different types of diet
Study NCT05585944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Genotyping of rs1883832C/T related single-nucleotide polymorphism
Description: Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
Study NCT05987176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutathera
Description: Dosage:~In total 14.8 GBq (400 mCi) 177Lu-DOTATATE administered in two equally divided doses. Each dose to be infused over 30 minutes.~Duration of treatment:~Two administrations of 177Lu-DOTATATE (each treatment 7.4 GBQ (200 mCi) at 8±1-week intervals, which can be extended to 16 weeks for resolving acute toxicity.
Study NCT05188742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: mirabegron 50mg QD
Study NCT04232657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: 39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.
Study NCT04232657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.
Study NCT05188742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TTNS
Description: transcutaneous tibial nerve stimulation
Study NCT04232657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
Study NCT04917770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab in combination with Multimodality Radiotherapy
Description: Participants will be treated with sintilimab in combination with multimodality radiotherapy
Study NCT05237310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy using a standard Fujifilm colonoscope
Study NCT05237310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G-EYE Colonoscopy
Description: G-EYE Colonoscopy performed using SMART Medical G-EYE Colonoscope
Study NCT05237310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD-EYE
Description: Colonoscopy performed using with the aid of Fujifilm CAD-EYE artificial intelligence
Study NCT04826679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab, nab-paclitaxel, cisplatin
Description: Patients receive Camrelizumab IV on day 1, nab-paclitaxel IV on day 1 and cisplatin IV on day 1.~Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Study NCT04930796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)
Study NCT05029050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Continous intravenous infusion
Study NCT05029050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Continous intravenous infusion
Study NCT05029050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natriumchlorid
Description: Continous intravenous infusion NaCl
Study NCT05531747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: A maximum of 2 superficial skin biopsies (epidermis/dermis), allowing 10 hair follicles to be obtained, at the edge of the affected area, in healthy territory (excluding the face and folds but not excluding the pubic region), at initiation visit.
Study NCT05531747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 42mL of blood (6 tubes of 7mL) sampled at initiation visit
Study NCT05014061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Adenosine infusion 70 µg/kg/min for 6 hours
Study NCT05999162 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally invasive surgery
Description: Minimally invasive surgery includes laparoscopic surgery or robotic surgery for the treatment of colorectal surgery.
Study NCT05986084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injection [Apretude]
Description: Injection
Study NCT05808634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA3182
Description: Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM
Study NCT05402033 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey / Interview Group
Description: Patients with any cancer type who are informed that they may be eligible for participation in any phase therapeutic cancer clinical trial by their treating physician (typically a clinical oncologist) will be provided information about the Financial Reimbursement Program. Patients who enroll to therapeutic cancer clinical trial will be eligible for the reimbursement program and offered an opportunity to participate in this study.
Study NCT06160102 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Develop and implement the Framework for safe drug use in people with intellectual and/or developmental disabilities
Description: Collection and analysis of drug lists and information about the users. Open / participatory observations of staff and residents during drug handling. Interviews/focus groups with residents, family, staff in the service, GPs and pharmacy staff. Interdisciplinary drug reviews based on the IMM method drug reviews, further developed by the researchers in the project.~Design thinking. We use a design process with five stages: empathy, define, generate ideas, prototype and test. This involves user participation and experience to design the most optimal solution for the framework.~Evaluate the framework, observations, interviews, questionnaires. Health economic evaluation.
Study NCT05241249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol
Description: Study Drug: Bethanechol (generic), supplied as 50mg oral tablets. Subjects will take 2 tablets (100mg) twice daily. Medication should be taken 1 hour before meals in AM and PM. Medication will be purchased commercially and dispensed at the research pharmacy.
Study NCT05241249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with gemcitabine at a dose of 1000 mg/m2
Study NCT05241249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with nab-paclitaxel dose at 125 mg/m2
Study NCT05896007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 1st year in 2 years of follow-up
Study NCT05896007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 ivgtt, D0 of each 28-day cycle
Study NCT05896007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5 g/m\^2 ivgtt, D1 of each 28-day cycle
Study NCT05896007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m\^2 ivgtt, D1-D5 of each 28-day cycle
Study NCT05255003 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: I. Platelet count 25-50,000/µL: 0.5mg/kg subcutaneously twice daily~II. Platelet count \< 25,000/µL: hold anticoagulation
Study NCT05255003 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: I. Platelet count 25-50,000/µL: 0.5mg/kg subcutaneously twice daily~II. Platelet count \< 25,000/µL: hold anticoagulation
Study NCT05255003 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: I. Platelet count 25-50,000/µL: 100 IU/kg subcutaneously daily for the first month of an acute VTE then 75 U/kg~II. Platelet count \< 25,000/µL: hold anticoagulation
Study NCT05255003 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: I. Platelet count 25-50,000/µL: 100 IU/kg subcutaneously daily for the first month of an acute VTE then 75 U/kg~II. Platelet count \< 25,000/µL: hold anticoagulation
Study NCT05255003 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin
Description: I. Platelet count 25-50,000/µL: 87.5 units/kg subcutaneously daily~II. Platelet count \< 25,000/µL: hold anticoagulation
Study NCT05255003 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: I. Platelet count 25-50,000/µL: 87.5 units/kg subcutaneously daily~II. Platelet count \< 25,000/µL: hold anticoagulation
Study NCT04819321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting® System
Description: A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
Study NCT05406908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tozinameran
Description: Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)
Study NCT05406908 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tozinameran
Description: Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)
Study NCT06112964 — intervention group
Intervention type: PROCEDURE
Intervention: MRI/ Functional MRI
Description: Participants will undergo an MRI scan lasting approximately 1 hour to examine the structure and function of the brain. During the scan, they will also be asked to perform computer based tasks. This is called functional MRI.
Study NCT06112964 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-reported questionnaires
Description: Participants will complete questionnaires covering subjective measures relating to food attitudes and intake, and report-based measures of relevant psychopathology including depression and anxiety. These will be derived from standardised scales already used clinically, including the setting of eating disorders and normative studies of the neuroscience of appetite.
Study NCT06112964 — intervention group
Intervention type: BEHAVIORAL
Intervention: Computer based tasks
Description: Participants will complete computer based tasks which are focused specifically on aspects of appetite-related and reward behaviours. Typically, such behaviours are characterised under the following sub-headings:~i) Motivation (the amount of effort, cognitive or physical, that a person is prepared to expend in order to gain access to food), ii) Valuation (the relative rating of foods in comparison to each other and to non-food items), and iii) Hedonic response (the subjective pleasure experienced in consumption) to food intake
Study NCT05527938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based intervention
Description: 1. Establishing management teams.~2. Establishment of a nursing intervention team.~3. Daily uploading of health intervention records~4. Regularly delivering related health knowledge.~5. Home visiting~6. Psychological guidance. The health teachers in the team should closely understand the psychological trends of the patients during the telephone follow-up and home visits and verbally communicate more with the children to stimulate them to develop good living habits and increase their confidence in healing.
Study NCT05915039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Assisted Learning (CAL) Module
Description: The students assigned to Group A will undergo interactive CAL module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines.
Study NCT05541887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscadine Wine Polyphenol
Description: dealcoholized muscadine wine with alcohol content \<0.5% with addition of 50ppm of sodium metabisulfite for preservation
Study NCT05541887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: this placebo beverage is formulated with matching sugar and organic acid content to the muscadine wine polyphenol. Food coloring is added to match the color of the intervention. 50ppm of sodium metabisulfite for preservation
Study NCT03649919 — intervention group
Intervention type: OTHER
Description: Patients receive routine diagnostic and treatment medications.
Study NCT06089382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles or tumour recurrence）
Study NCT06089382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8mg orally once a day for 1 year
Study NCT06089382 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Description: One cycle of TACE postoperatively
Study NCT04834271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Side-lying external rotation exercise with a dumbbell
Description: Side-lying external rotation exercise with a dumbbell (20-30% 1RM). 2 times per week during 4 weeks.
Study NCT04834271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Side-lying external rotation exercise with a dumbbell with 40% arterial occlusion pressure blood flow restriction
Description: Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 40% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
Study NCT04834271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Side-lying external rotation exercise with a dumbbell with 80% arterial occlusion pressure blood flow restriction
Description: Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 80% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
Study NCT05026567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 ml of DORMICUM® Midazolam Hydrochloride (15 mg/3 mL)
Description: Intramuscular injection
Study NCT05026567 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ZENEO® Midazolam (10 mg/0.625 mL) on bare skin in thigh
Description: Intramuscular injection
Study NCT05026567 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ZENEO® Midazolam (10 mg / 0.625 mL) on bare skin in ventrogluteal area
Description: Intramuscular injection
Study NCT05026567 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ZENEO® Midazolam (10 mg / 0.625 mL) through clothing in thigh
Description: Intramuscular injection
Study NCT04739566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO twice daily
Study NCT04739566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO once daily
Study NCT06190366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bloodletting acupuncture at the fossa poplitea
Description: This group is treated with bloodletting acupuncture at the fossa poplitea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
Study NCT06190366 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bloodletting acupuncture at the regio glutaea
Description: This group is treated with bloodletting acupuncture at the regio glutaea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
Study NCT04943783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: One with the intervention (Atorvastatin, 20mg OD), 20 patients for this arm.
Study NCT05442112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Patient Message
Description: The intervention is a detailed patient message containing information on strategies for exercise in MS, how to maintain proper sleep, and dietary improvements to maximize health. These strategies are derived from information provided by the National MS Society in their website and covers these topics in greater detail than would normally be addressed in a normal clinic visit. The message also directs patients to the National MS Society website if they would like more information.
Study NCT05619289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: One-time, oral dose of 300,000 IU of Ergocalciferol administered via 6 capsules.
Study NCT05619289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One-time, oral dose of 6 inert capsules matched to the active comparator
Study NCT04593628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect for Caregivers
Description: The STAR Center developed Connect for Caregivers to help improve connectedness among older caregivers of individuals with Alzheimer's Disease and Related Dementias (ADRD). Connect for Caregivers includes three components: (1) psychoeducational materials on the importance of connectedness for health and well-being; (2) a card sort-based 'discussion prioritization tool' that systematizes and routinizes the process of identifying and prioritizing barriers to connectedness; (3) personalized resources to address the identified barriers/targets. We will tailor Connect for Caregivers for Hispanic/Latino and Spanish-speaking caregivers guided by the Selective and Directed Treatment Adaptation Framework. The intervention is given once during the study.